Currently, there are 31.68M common shares owned by the public and among those 25.93M shares have been available to trade.
The company’s stock has a 5-day price change of 4.71% and 20.89% over the past three months. SLNO shares are trading 29.12% year to date (YTD), with the 12-month market performance up to 123.24% higher. It has a 12-month low price of $21.30 and touched a high of $55.56 over the same period. SLNO has an average intraday trading volume of 466.22K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 3.49%, 6.17%, and 15.18% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Soleno Therapeutics Inc (NASDAQ: SLNO) shares accounts for 80.54% of the company’s 31.68M shares outstanding.
It has a market capitalization of $2.02B and a beta (3y monthly) value of -1.42. The earnings-per-share (ttm) stands at -$2.43. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.97% over the week and 4.99% over the month.
Earnings per share for the fiscal year are expected to increase by 0.90%, and 13.09% over the next financial year. EPS should shrink at an annualized rate of 15.00% over the next five years, compared to 24.34% over the past 5-year period.
Looking at the support for the SLNO, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on September 03, 2024, with the firm’s price target at $70. Robert W. Baird coverage for the Soleno Therapeutics Inc (SLNO) stock in a research note released on May 10, 2024 offered a Outperform rating with a price target of $72. Piper Sandler was of a view on February 05, 2024 that the stock is Overweight, while Stifel gave the stock Buy rating on January 23, 2024, issuing a price target of $63. Guggenheim on their part issued Buy rating on November 21, 2023.
